GlassScriptPhysician profile
Cynthia A Cid
NPI 1992763403
$2,037.37
in general payments reported to CMS, 2019-2025
20 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $87.42 · 2021: $227 · 2022: $522 · 2023: $350 · 2024: $296 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,027 · Entertainment: $34.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,027.27 |
| Entertainment | $34.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $488.02 | 2020-2025 | Myday Contact Lens, Misight Contact Lens |
| Alcon Vision LLC | $306.70 | 2019-2025 | Precision 1, Total30, Rocklatan |
| Bausch & Lomb Americas INC. | $198.20 | 2022-2025 | Infuse, Btod |
| Abbvie INC. | $179.81 | 2023-2025 | Alphagan P, Vuity, Lumigan |
| Novartis Pharmaceuticals Corporation | $124.68 | 2021-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $121.80 | 2019-2021 | |
| Glaukos Corporation | $101.75 | 2021-2022 | |
| Oyster Point Pharma, INC. | $87.11 | 2022-2025 | Tyrvaya, Ryzumvi |
| Notal Vision, INC. | $74.37 | 2022 | |
| Allergan, INC. | $64.72 | 2022 | |
| Eyevance Pharmaceuticals LLC | $62.01 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $46.52 | 2021-2025 | |
| Optos, INC. | $34.81 | 2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Lkc Technologies, INC. | $32.70 | 2024 | |
| Maculogix, INC. | $28.08 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $23.98 | 2019 | |
| Kala Pharmaceuticals, INC. | $21.86 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $20.60 | 2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $12.04 | 2019 | |
| Abb Con-Cise Optical Group LLC | $7.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Cid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.